UK ' s Destiny Pharma Taps AIM Market to Fund ' Superbug ' Drugs UK ' s Destiny Pharma Taps AIM Market to Fund ' Superbug ' Drugs
British biotech firm Destiny Pharma is aiming to raise more than 10 million pounds ($12.9 million) of new equity to develop drugs that target antibiotic-resistant bacterial infections, or superbugs, in hospitals, it said on Friday.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
More News: Biotechnology | Health | Hospitals | Infectious Diseases | Pharmaceuticals | Superbugs | UK Health